Lykos Therapeutics Announces Completion of European Phase 2 Study for MDMA-Assisted Therapy for PTSD

Lykos Therapeutics California

for drugs that, if approved, would represent significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.2 If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy.

Midomafetamine (MDMA) capsules have not been approved by any regulatory agency. The safety and efficacy of midomafetamine have not been established for the treatment of PTSD. Investigational midomafetamine is also being studied in other indications.

Lykos Therapeutics (Formerly MAPS PBC)
At Lykos Therapeutics, a public benefit corporation (PBC) founded by MAPS, our mission is to transform mental healthcare. We're applying our decades in evidence-based research to develop investigational psychedelics to catalyze therapeutic approaches for mental health conditions. We are relentlessly exploring and reimagining novel approaches to address unmet needs in the mental healthcare space, with an initial focus on PTSD. As a PBC, we are focused on delivering positive impact on our people, communities and society. To learn more visit us at www.lykospbc.com and on LinkedIn, X, Instagram and Facebook.

1 Burri A, Maercker A. Differences in prevalence rates of PTSD in various European countries explained by war exposure, other trauma and cultural value orientation. BMC Res Notes. 2014;7:407. doi: 10.1186/1756-0500-7-407

2 FDA Priority Review. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review. Accessed January 2024.

Logo - https://mma.prnewswire.com/media/2394273/Lykos_Therapeutics_logo_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lykos-therapeutics-announces-completion-of-european-phase-2-study-for-mdma-assisted-therapy-for-ptsd-302126010.html